AstraZeneca (AZN.US) plans to invest $50 billion in the United States before 2030, while European pharmaceutical companies are speeding up their tax avoidance strategies.

According to the Smart Financial News APP, AstraZeneca (AZN.US) announced plans to invest $50 billion in the United States by 2030, becoming the latest European pharmaceutical company to accelerate its layout in the United States due to potential import drug tariffs policies.